Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenhydramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.62 |
| ▸ | HRH2 | P25021 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL506882 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL30206347 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL25269204 | 0.81 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL25268546 | 0.81 | SLC6A2 (0.83) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL29096592 | 0.80 | LMNA (0.84) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL27912373 | 0.79 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL4064 | 0.79 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL12543374 | 0.79 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL25269472 | 0.78 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3LMNACHRM1 | |
| Diphenhydramine SCHEMBL25263363 | 0.78 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| US-20210299081-A1 | SOLID CANNABINOID FORMULATION FOR ORAL ADMINISTRATION | ACQUIOM AGENCY SERVICES LLC | 2021-09-30 | — | — | US | disclosed |
| CN-111729161-A | Methods and devices for compound delivery | 方特慕控股第一私人有限公司 | 2020-10-02 | — | — | CN | disclosed |
| EP-3698832-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | Fontem Holdings 1 B.V. (NL) | 2020-08-26 | — | — | EP | disclosed |
| US-20200253922-A1 | METHODS FOR NON-IRRITATING PULMONARY ADMINISTRATION OF CANNABINOIDS USING SOFT MIST INHALERS | ACQUIOM AGENCY SERVICES LLC | 2020-08-13 | — | — | US | disclosed |
| US-20200246404-A1 | FORMULATIONS | ACQUIOM AGENCY SERVICES LLC | 2020-08-06 | — | — | US | disclosed |
| EP-3096636-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2020-04-15 | — | — | EP | disclosed |
| US-20200069595-A1 | PHARMACEUTICAL FORMULATION AND SYSTEM AND METHOD FOR DELIVERY | RILENTO PHARMA, LLC | 2020-03-05 | — | — | US | disclosed |
| US-20200037638-A1 | FORMULATIONS | ACQUIOM AGENCY SERVICES LLC | 2020-02-06 | — | — | US | disclosed |
| CN-110636834-A | Preparation | 分子浸剂有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-106455705-A | Methods and devices for smoking urge relief | 方特慕控股第私人有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3096636-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | Fontem Holdings 1 B.V. (NL) | 2016-11-30 | — | — | EP | disclosed |
| EP-2925395-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-Nicotine Technology, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| CN-104955508-A | Methods and devices for compound delivery | NICOTINE TECHNOLOGY INC E | 2015-09-30 | — | — | CN | disclosed |
| US-20150216237-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 B.V. (NL) | 2015-08-06 | — | — | US | disclosed |
| WO-2015112750-A1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | E-NICOTINE TECHNOLOGY, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| CN-204147375-U | Be designed for the aerosol generation equipment producing condensation aerosol | NICOTINE TECHNOLOGY INC E | 2015-02-11 | — | — | CN | disclosed |
| US-20140190496-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014085719-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140144429-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299081-A1 | SOLID CANNABINOID FORMULATION FOR ORAL ADMINISTRATION | CNR1, CNR2, FAAH | HRH1 300/4885SLC6A2 214/4885SLC6A4 217/4885 |
| US-20200253922-A1 | METHODS FOR NON-IRRITATING PULMONARY ADMINISTRATION OF CANNABINOIDS USING SOFT MIST INHALERS | CNR1, CNR2, NCSTN | HRH1 264/4885SLC6A2 435/4885SLC6A4 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.